Thermo Fisher Scientific CTCF Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

0.1-0.5 µg/mL

-

Immunohistochemistry (Paraffin) (IHC (P))

0.5-1 µg/mL

-

Immunocytochemistry (ICC/IF)

5 µg/mL

-

Product Specifications

Species Reactivity

Human, Mouse, Rat

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

E.coli-derived human CTCF recombinant protein (Position: K521-R727). if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CTCF,uniProtId:P49711-1,ncbiNodeId:9606,antigenRange:521-727,antigenLength:727,antigenImageFileName:PA5-79087_CTCF_P49711-1_Rabbit.svg,antigenImageFileNamePDP:PA5-79087_CTCF_P49711-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

500 µg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS with 5mg BSA

Contains

0.05mg sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2746203

Product Specific Information

Reconstitute with 0.2 mL of distilled water to yield a concentration of 500 µg/mL.

Target Information

Transcriptional factor CTCF is a ubiquitously expressed 11-zinc finger domain containing, DNA-binding nuclear phosphoprotein that is involved in multiple aspects of normal gene regulation including transcriptional repression and activation, gene silencing, chromatin insulation and regulation of imprinted sites. CTCF uses different combinations of ZF domains and interacts with the CCCTC motif on the DNA. It can bind to HAT- and HDAC-containing complexes thereby influencing transcriptional activation or repression respectively. It is a multifunctional protein involved in the transactivation of APPB gene, silencing of c-myc gene, and insulation of human beta-globin and DMI myotonic dystrophy locus and imprinting control of IGF2 and H19 regions. CTCF has also been shown to regulate the transcription of Pax6 and IRAK2 promoter thereby opening a therapeutic avenue. Mutations in this gene have been associated with invasive breast cancers, prostate cancers and Wilms` tumors.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.